retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity π¨ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. π Mean body weight change at 80 weeks: β¬οΈ Triple Agonism Based Therapies for
Pay in 4 interest-free payments of $5.95 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 17 - Aug 22






![Cardiovascular disease continuum-GLP-1 action. Adapted from [46]](https://www.researchgate.net/publication/357072789/figure/fig1/AS:1146405179654167@1650335702879/Cardiovascular-disease-continuum-GLP-1-action-Adapted-from-46.png)



















